197 related articles for article (PubMed ID: 18329537)
1. Novel treatment approaches to fibrosis in scleroderma.
Distler J; Distler O
Rheum Dis Clin North Am; 2008 Feb; 34(1):145-59; vii. PubMed ID: 18329537
[TBL] [Abstract][Full Text] [Related]
2. Innovative therapies for systemic sclerosis.
Ong VH; Denton CP
Curr Opin Rheumatol; 2010 May; 22(3):264-72. PubMed ID: 20190640
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms and consequences of fibrosis in systemic sclerosis.
Denton CP; Black CM; Abraham DJ
Nat Clin Pract Rheumatol; 2006 Mar; 2(3):134-44. PubMed ID: 16932673
[TBL] [Abstract][Full Text] [Related]
4. Hematopoietic stem cell transplantation for systemic sclerosis: history and current status.
Burt RK; Milanetti F
Curr Opin Rheumatol; 2011 Nov; 23(6):519-29. PubMed ID: 21857226
[TBL] [Abstract][Full Text] [Related]
5. Innovative antifibrotic therapies in systemic sclerosis.
Beyer C; Distler O; Distler JH
Curr Opin Rheumatol; 2012 May; 24(3):274-80. PubMed ID: 22450392
[TBL] [Abstract][Full Text] [Related]
6. Systemic sclerosis: an update.
Varga J
Bull NYU Hosp Jt Dis; 2008; 66(3):198-202. PubMed ID: 18937632
[TBL] [Abstract][Full Text] [Related]
7. New pathogenic and therapeutic concepts in systemic sclerosis.
Hügle T; Huigens CA; van Laar JM
Arzneimittelforschung; 2009; 59(12):615-24. PubMed ID: 20108646
[TBL] [Abstract][Full Text] [Related]
8. Autologous HSCT in systemic sclerosis: a step forward.
Farge D; Gluckman E
Lancet; 2011 Aug; 378(9790):460-2. PubMed ID: 21777973
[No Abstract] [Full Text] [Related]
9. Immunological reconstitution after autologous hematopoietic stem cell transplantation in patients with systemic sclerosis: relationship between clinical benefits and intensity of immunosuppression.
Bohgaki T; Atsumi T; Bohgaki M; Furusaki A; Kondo M; Sato-Matsumura KC; Abe R; Kataoka H; Horita T; Yasuda S; Amasaki Y; Nishio M; Sawada K; Shimizu H; Koike T
J Rheumatol; 2009 Jun; 36(6):1240-8. PubMed ID: 19447934
[TBL] [Abstract][Full Text] [Related]
10. [Long-term treatments for systemic sclerosis: what are the perspectives?].
Mouthon L; Agard C; Garcia De La Peña-Lefebvre P; Guillevin L
Ann Med Interne (Paris); 2002 Jun; 153(4):265-75. PubMed ID: 12218893
[TBL] [Abstract][Full Text] [Related]
11. Molecular pathways as novel therapeutic targets in systemic sclerosis.
Trojanowska M; Varga J
Curr Opin Rheumatol; 2007 Nov; 19(6):568-73. PubMed ID: 17917537
[TBL] [Abstract][Full Text] [Related]
12. Autologous Stem cell Transplantation International Scleroderma (ASTIS) trial: hope on the horizon for patients with severe systemic sclerosis.
van Laar JM; Farge D; Tyndall A
Ann Rheum Dis; 2005 Oct; 64(10):1515. PubMed ID: 16162905
[No Abstract] [Full Text] [Related]
13. [Do specific antifibrotic properties of immunosuppressive drugs used in the treatment of systemic sclerosis exist?].
Verrecchia F; Michel L; Keshtmand H; Wang Y; Launay D; Farge D
Rev Med Interne; 2009 Nov; 30(11):955-62. PubMed ID: 19349102
[TBL] [Abstract][Full Text] [Related]
14. Future targets in the management of systemic sclerosis.
Tyndall A; Matucci-Cerinic M; Müller-Ladner U
Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii49-53. PubMed ID: 19487225
[TBL] [Abstract][Full Text] [Related]
15. Adult stem cell treatment of scleroderma.
Tyndall A; Furst DE
Curr Opin Rheumatol; 2007 Nov; 19(6):604-10. PubMed ID: 17917542
[TBL] [Abstract][Full Text] [Related]
16. Systemic sclerosis refractory disease: from the skin to the heart.
Almeida I; Faria R; Vita P; Vasconcelos C
Autoimmun Rev; 2011 Sep; 10(11):693-701. PubMed ID: 21575745
[TBL] [Abstract][Full Text] [Related]
17. Disease-modifying treatment in systemic sclerosis: current status.
Quillinan NP; Denton CP
Curr Opin Rheumatol; 2009 Nov; 21(6):636-41. PubMed ID: 19726995
[TBL] [Abstract][Full Text] [Related]
18. Phototherapy: a promising treatment option for skin sclerosis in scleroderma?
Sunderkötter C; Kuhn A; Hunzelmann N; Beissert S
Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii52-iii54. PubMed ID: 16987838
[TBL] [Abstract][Full Text] [Related]
19. Intravenous immunoglobulin treatment recovers the down-regulated levels of Th1 cytokines in the sera and skin of scleroderma patients.
Kudo H; Jinnin M; Yamane K; Makino T; Kajihara I; Makino K; Honda N; Nakayama W; Fukushima S; Ihn H
J Dermatol Sci; 2013 Jan; 69(1):77-80. PubMed ID: 23102713
[No Abstract] [Full Text] [Related]
20. [Current treatment of systemic sclerosis. Part II. Vascular and antifibrotic treatment].
Sicińska J; Rudnicka L
Pol Merkur Lekarski; 2008 Aug; 25(146):196-200. PubMed ID: 18942347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
